PTJ
MDGL icon

Paul Tudor Jones’s Madrigal Pharmaceuticals MDGL Stock Holding History

Paul Tudor Jones’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-400
Closed -$233K – 4029
2025
Q4 		$233K Sell
400
-400
-50% -$204K ﹤0.01% 3203
2025
Q3 		$367K Sell
800
-1,100
-58% -$410K ﹤0.01% 2865
2025
Q2 		$575K Buy
1,900
+800
+73% +$238K ﹤0.01% 2505
2025
Q1 		$364K Buy
+1,100
New +$361K ﹤0.01% 2475
2024
Q3 		– Sell
-3,400
Closed -$953K – 2953
2024
Q2 		$953K Buy
3,400
+1,200
+55% +$286K ﹤0.01% 1485
2024
Q1 		$587K Buy
+2,200
New +$518K ﹤0.01% 1579

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Paul Tudor Jones's MDGL Position: Q2 2026 in Review

Paul Tudor Jones reduced its Madrigal Pharmaceuticals (MDGL) stake by 1% in Q2 2026, selling an estimated $62K and leaving 11,509 shares worth $6.18M. The position accounts for 0.01% of the portfolio, ranked #1139.

Paul Tudor Jones first reported a position in MDGL in Q2 2013 and has held it in 16 quarters since. 411 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Paul Tudor Jones held 11,509 shares of Madrigal Pharmaceuticals worth $6.18M as of Q2 2026.
  • Paul Tudor Jones sold 121 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $62K.
  • Madrigal Pharmaceuticals made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1139 holding.
  • Paul Tudor Jones first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 16 quarters since.
  • 411 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.